Roche schizophrenia drug that failed PhIII gets a new life in rare disorder as OrbiMed leads $90M for startup

Amber Tong

Until a few years ago, GlyT1, a glycine transporter, seemed like a promising target for an add-on therapy to treat negative symptoms of schizophrenia. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roche schizophrenia drug that failed PhIII gets a new life in rare disorder as OrbiMed leads $90M for startup

Amber Tong

Sign up to read this article for free.

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Acadia snaps up an essential tremor drug after field's summer setbacks

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Roche schiz­o­phre­nia drug that failed PhI­II gets a new life in rare dis­or­der as Or­biMed leads $90M for start­up

Amber Tong

Sign up to read this article for free.

more like this

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Aca­dia snaps up an es­sen­tial tremor drug af­ter field­'s sum­mer set­backs

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Roche schizophrenia drug that failed PhIII gets a new life in rare disorder as OrbiMed leads $90M for startup

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Acadia snaps up an essential tremor drug after field's summer setbacks

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?